Nephroprotective and clinical potential of statins in dialyzed patients.
BACKGROUND
The combination of increased cardiovascular mortality and vascular complications due to dyslipidaemia in chronic kidney disease (CKD) has focused attention onto the potential beneficial effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) inhibitors (statins) on the course of CKD.


OBJECTIVE
To examine the use of statins in CKD.


METHODS
A review of relevant literature.


CONCLUSIONS
Current evidence from clinical trials in CKD patients on maintenance dialysis is limited. Therefore, the routine use of statins in this population remains the decision of individual physicians in discussion with their patients.
Medical University of Lodz, Department of Nephrology, Hypertension and Family Medicine, Lodz, Poland.
Jacek
J
Rysz
Wilbert S
WS
Aronow
Robert S
RS
Stolarek
Simon
S
Hannam
Dimitri P
DP
Mikhailidis
Maciej
M
Banach
D050197:Atherosclerosis / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D006348:Cardiac Surgical Procedures; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood / Q000502:physiology; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003928:Diabetic Nephropathies / Q000201:enzymology / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D004730:Endothelium, Vascular / Q000378:metabolism / Q000473:pathology; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005355:Fibrosis; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000150:complications / Q000378:metabolism / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D008055:Lipids / Q000097:blood; D020782:Matrix Metalloproteinases / Q000378:metabolism; D015337:Multicenter Studies as Topic; D011183:Postoperative Complications / Q000517:prevention & control; D006435:Renal Dialysis
D016326:Extracellular Matrix Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D002784:Cholesterol; D020782:Matrix Metalloproteinases